Navigation Links
Van Andel Institute Researchers Find Potential Drug Target For Aggressive Form Of Lymphoma
Date:6/22/2012

GRAND RAPIDS, Mich., June 22, 2012 /PRNewswire/ -- A discovery by Van Andel Institute  researchers has identified a potential drug target for NK/T-cell lymphoma, a type of cancer responsible for claiming the life of a close friend and fellow researcher.

A study authored by Bin Tean Teh, M.D., Ph.D., and published this week in Cancer Discovery, a journal of the American Association for Cancer Research, notes that a substantial proportion of NK/T-cell lymphomas harbor Janus Kinase 3 (JAK3) gene mutations, indicating that patients with these lymphomas might benefit from treatment with a Janus Kinase inhibitor.

Lymphoma is a cancer that begins in the immune system. NK/T-cell lymphoma is an aggressive form of the disease with a poor prognosis that is rare in the United States, though prevalent throughout much of Asia. According to Teh, the only case ever recorded in Grand Rapids, Michigan was that which struck close friend and fellow Van Andel Institute researcher, Han-Mo Koo, Ph.D., in 2004. 

Teh and Koo began working together at Van Andel Institute in 1999 as a part of a group of founding principal investigators. Koo's promising work identifying genetic targets for anti-cancer drug development for melanoma and pancreatic cancer was cut short when he passed away from NK/T-cell lymphoma in 2004, at the age of 40. Before Koo died, Teh promised him that he would dedicate his efforts toward finding the genetic basis of the disease.

"The passing of my colleague, whom I was very close to, was the reason that I started studying NK/T-cell lymphoma. It has been a complicated puzzle, but I feel that we have pieced together enough that we will have an impact on a large number of patients with the disease," said Teh, director of the National Cancer Center Singapore-Van Andel Research Institute Translational Research Laboratory at the NCCS, and professor at the Duke-NUS Graduate Medical School in Singapore.

"We are currently putting together a proposal to test JAK inhibitors as a treatment for NK/T-cell lymphoma with JAK3 mutations," said Teh. "I am hopeful that we might have found a molecular target for the treatment of a least some patients with this otherwise fatal disease."   


'/>"/>
SOURCE Van Andel Institute
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine
2. Softway Solutions Develops Award-Winning Health App for Texas Heart Institute
3. Argus Health Systems to Showcase Customizable Product for Medical Drug Claim Compliance at AHIP Institute 2012
4. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
5. Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital Sign Strategic Alliance to Further Cancer Research
6. Scripps Research Institutes Richard A. Lerner Wins Prince of Asturias Award for Scientific and Technical Research
7. The Illinois Back Institute Helps Patient Beat Debilitating Back Pain
8. The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease
9. The Rogosin Institute and Hebrew Home Collaborate to Provide New Dialysis Service for Residents and Patients
10. Roskamp Institute Reports Beneficial Effects of Nutritional Supplementation with Anatabine in an Animal Model of Multiple Sclerosis
11. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):